儿童伯基特淋巴瘤患者来源异种移植模型再现疾病特征并用于治疗研究
伯基特淋巴瘤占儿童青少年B细胞非霍奇金淋巴瘤近三分之二,强化化疗后生存率超90%,但复发难治者预后差。本研究建立儿童伯基特淋巴瘤患者来源异种移植(PDX)资源,可捕获并维持肿瘤异质性,用于表征肿瘤及识别治疗抵抗细胞群。
要点
- 儿童伯基特淋巴瘤PDX模型可捕获并维持肿瘤异质性
- PDX资源可用于识别与治疗抵抗相关的细胞群
- 为研究复发难治伯基特淋巴瘤提供模型工具
核心结论
- 建立的儿童伯基特淋巴瘤PDX资源能够捕获并维持肿瘤异质性,可用于表征肿瘤和识别治疗抵抗细胞群。
研究设计与样本
- 建立儿童伯基特淋巴瘤患者来源异种移植(PDX)资源。
主要发现
- PDX资源捕获并维持了肿瘤异质性。
- PDX可用于更好地表征肿瘤并识别负责治疗抵抗的细胞群。
关键数值与推荐
- 伯基特淋巴瘤占儿童和青少年B细胞非霍奇金淋巴瘤近三分之二。
- 伯基特淋巴瘤以MYC易位和快速细胞周转为特征。
- 含LMB方案的强化化疗使生存率超过90%。
- 复发和难治性疾病发生率达10%。
临床怎么用
- PDX资源可作为研究儿童伯基特淋巴瘤生物学和治疗抵抗的模型。
- 利用PDX识别治疗抵抗细胞群可能有助于改善复发难治患者的预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
引用
- Forde S, Matthews JD, Jahangiri L, et al. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. Br J Haematol. 2020. PMID: 32880915. doi:10.1111/bjh.17043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。